Get the Weekly Intelligence Brief — top committee picks every Sunday.
HLN · NYSE · STOCK

Haleon (HLN) Stock Analysis

Healthcare Updated October 10, 2026
$9.31
52W $8.65 – $11.28
53/100
$41.04B
19.3
0.24
AI Committee Verdict
Watch
53/100
Conviction: Contested · 33% agreement · 6 analysts
+6.9%
-0.1%
137.40:1
Contested

Is HLN Bullish or Bearish?

Mixed. Innellis AI committee rates Haleon plc (HLN) Watch with a composite score of 53/100 , based on 6 analysts with 33% agreement. Last updated October 10, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +6.74 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -13.26 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. News Analyst sees a compelling case — news sentiment is positive (+0.33 across 5 articles, 14d). Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • MACD histogram positive -- bullish momentum — Technical
  • Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
  • News sentiment is positive (+0.33 across 5 articles, 14d) — News
Bear Case
  • Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
  • Price structure making lower highs and lower lows — Technical
  • Trend and market structure agree -- coherent bearish picture — Technical
  • Current ratio of 0.92 is tight -- limited short-term liquidity cushion — Risk
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of October 10, 2026
Overall Committee Score
53/100
Agreement
33%
Analysts
6
Conviction
Contested
Sector Rank
Top 76%
of 192 Healthcare peers
Value Analyst neutral
58 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
Growth Analyst bearish
38 / 100 · Moderate confidence
Growth story is weak, decelerating, or inconsistent
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst neutral
56 / 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
− Price structure making lower highs and lower lows
Risk Analyst bearish
35 / 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Current ratio of 0.92 is tight -- limited short-term liquidity cushion
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst bullish
68 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.33 across 5 articles, 14d)
Portfolio Manager bearish
30 / 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Open Full Terminal →

Investment Thesis Evolution

Committee score weakened from 56.8 to 53.3.

Analyst-level changes:
  • News Analyst: score 72->68 (-4); +1 bullish signal(s).
  • Risk Analyst: stance neutral->bearish; score 52->35 (-18).

Comparing 2026-10-09 to 2026-10-10 (1 day apart).

Technical Analysis

RSI (14)
63.8
Neutral
MACD Histogram
0.043
Bullish Momentum
Trend Direction
Downtrend
Weekly: Downtrend
Market Structure
Lh Ll
Support
$9.30
Resistance
$9.95
Bollinger %B
0.71
Inside Bands
Price vs Moving Averages
EMA 9
$9.09 Above
EMA 21
$9.18 Above
EMA 50
$9.39 Below
EMA 200
$9.63 Below

Fundamental Analysis

Valuation
59
Growth
52
Profitability
68
Financial Health
50
Cash Flow
70
Valuation
P/E Ratio 19.3×
P/B Ratio 1.90×
PEG Ratio 3.27
Dividend Yield 2.09%
52W High $11.28
52W Low $8.65
Quality & Growth
ROE 994.4%
ROA 500.6%
Gross Margin 6556.7%
Operating Margin 2135.0%
Revenue Growth YoY —
Debt / Equity 0.50
AI Fundamental Assessment
P/E ratio of 19.3 (inexpensive relative to a 15-40x range); Price-to-book of 1.9x; PEG ratio of 3.3 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 9.9%; Return on assets of 5.0%; Net margin of 14.6%; Gross margin of 65.6%; Current ratio of 0.69 (tight short-term liquidity); Debt-to-equity of 0.50; Free cash flow per share is positive (0.27); Most recent quarter beat estimates by 7.2%; EPS growth decelerating (+19.3% -> -5.7% QoQ); Analyst estimates rising over recent quarters
Get the Full HLN Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime